Skip to main content

Table 4 Relationship between anti-C1q antibody and other disease parameters among patients under study

From: Association of anti-nuclesome and anti C1q antibodies with lupus nephritis in an Egyptian cohort of patients with systemic lupus erythematosus

Variable

n (%) or meanā€‰Ā±ā€‰SD

Positive

Anti-C1q

(nā€‰=ā€‰34)

Negative

Anti-C1q

(nā€‰=ā€‰46)

t/x2

P value

Clinical features

Arthritis

31 (91.2)

41 (89.1)

0.091

0.763

Pleurisy

15 (35.7)

27 (58.7)

1.666

0.197

Fever

19 (55.9)

20 (43.5)

1.204

0.273

Malar rash

20 (58.8)

30 (65.2)

0.341

0.559

Oral ulcers

17 (50.0)

21 (45.7)

0.148

0.700

Alopecia

13 (38.2)

21 (61.8)

0.440

0.507

Photosensitivity

11 (32.4)

20 (43.5)

1.020

0.313

Neurologic manifestations

6 (17.6)

14 (30.4)

1.705

0.192

APS

6 (17.6)

13 (28.3)

1.216

0.270

Vasculitis

10 (29.4)

4 (8.7)

5.811

0.016

Pericarditis

5 (14.7)

5 (10.9)

0.263

0.608

Discoid rash

4 (11.8)

2 (4.3)

1.550

0.213

Myositis

0 (0.0)

1 (2.2)

0.748

0.387

Nephritis

23 (67.6)

17 (37.0)

7.366

0.007

ECLAM

Ā 

4.2ā€‰Ā±ā€‰1.9

3.5ā€‰Ā±ā€‰2.2

1.572

0.120

Laboratory features

ESR (mm/1st hour)

57.7ā€‰Ā±ā€‰32.5

41.1ā€‰Ā±ā€‰26.8

2.500

0.015

Serum creatinine (Ī¼mol/L)

0.9ā€‰Ā±ā€‰0.7

0.8ā€‰Ā±ā€‰0.3

0.643

0.500

Serum albumin (g/dl)

3.6ā€‰Ā±ā€‰0.5

4.0ā€‰Ā±ā€‰0.8

2.677

0.009

Low C3ā€‰<ā€‰90 (mg/dl)

20 (58.8)

16 (34.8)

4.565

0.033

Low C4ā€‰<ā€‰10 (mg/dl)

12 (35.3)

7 (15.2)

4.351

0.037

  1. APS Antiphospholipid syndrome, ESR Erythrocyte sedimentation rate, ECLAM European Consensus Lupus Activity Measurement